Skip to main content
Analysis boosts fluvoxamine for COVID, but what’s the evidence?
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Analysis boosts fluvoxamine for COVID, but what’s the evidence?
User login
Username
Password
Reset your password
Concept
Lead
score
COVID-19
1
0.91
Antiviral Agents
0
0.9
COVID-19 Treatment
0
0.53
Meta-Analysis
0
0.44
Erectile Dysfunction
0
0.43
Hospital
0
0.29
Depression
0
0.18
Toxicology
0
0.18
Activism
0
0.15
Antidepressant drug
0
0.15
Canada
0
0.15
Clinical Research
0
0.15
Drug Interaction
0
0.15
Pennsylvania
0
0.15
Post-Acute Sequelae of SARS-CoV-2 Infection
0
0.15
Washington
0
0.15
Obesity
0
0.11
Specialty
Lead
score
Infectious Diseases
1
1
Family Medicine/Primary Care
0
1
Internal Medicine
0
1
Public Health & Prevention
0
1
Pharmacist
0
0.94
Pulmonary Medicine
0
0.9
Diabetes & Endocrinology
0
0.62
Urology
0
0.43
Emergency Medicine
0
0.33
Psychiatry
0
0.33
Medscape Today
0
0.26
Hospital Medicine
0
0.21
Edit Tags